Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
India business contributes to a stellar performance
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
He will be stationed at the company HQ in Bengaluru, India
Aditya Puri former MD of HDFC bank joins Solara board as chairman
Startup receives US $ 5 million in first round of funding
NPPA has capped the trade margin for Oxygen Concentrators at 70% on Price to Distributor (PTD) level
Complementary business models are the reason for the acquisition
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
Subscribe To Our Newsletter & Stay Updated
